Immuno-Oncology | Specialty

Dr. Jeffrey Weber on Ipilimumab for Melanoma

February 2nd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the EORTC 18701 study, which compared ipilimumab with placebo for patients with stage III node-positive melanoma.

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

January 29th 2015

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, talks about the toxicity of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

PD-1 Inhibition: The Changing Treatment Paradigm for Melanoma

January 29th 2015

An increased understanding of tumor immunology has led to seven new melanoma drug approvals since 2011, including the recent approvals of the PD-1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda).

Targeted Therapies and Immunotherapies Are Transforming Outcomes in Advanced NSCLC

January 28th 2015

Ten or 15 years ago, a diagnosis of advanced non– small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.

Brahmer Expects Rapid Approval for First PD-1 Inhibitor in Lung Cancer

January 25th 2015

Immune checkpoint inhibitors targeted against PD-1 and its ligand PD-L1 have rapidly advanced as treatments for patients with melanoma and non–small cell lung cancer (NSCLC), following their initial debut in 2012.

Complexities of Translating PD-1/PD-L1 Agents to Clinical Practice Emerge

January 20th 2015

As varying immunotherapy options become available for different types of cancers, researchers will have to take the next steps in clinical studies and in practice before the growing excitement over emerging agents can truly be translated into beneficial new therapies for patients.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Latest News & Insight: January 15, 2015

January 15th 2015

Updated KEYNOTE-012 Shows Activity for Pembrolizumab in Gastric Cancer

January 15th 2015

Among patients with metastatic gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab, the agent showed promising antitumor activity and a manageable toxicity profile.

Dendreon Revenue Rises, Despite Restructuring

January 14th 2015

Increased utilization of the autologous cellular immunotherapy sipuleucel-T (Provenge) led to a $20.1 million improvement in total revenue in 2014 for the manufacturer Dendreon, when compared with 2013.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice

January 13th 2015

To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.

Nivolumab Improves Survival in Phase III NSCLC Study

January 12th 2015

Nivolumab improved survival versus docetaxel in patients with pretreated squamous cell non–small cell lung cancer in the phase III CheckMate-017 trial.

Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration

January 9th 2015

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

Latest News & Insight: January 8, 2015

January 8th 2015

Changing Landscape in the Treatment of Relapsed/Refractory Hodgkin Lymphoma

December 29th 2014

Newer drugs for patients with relapsed and refractory Hodgkin lymphoma

FDA Approves Nivolumab for Advanced Melanoma

December 22nd 2014

The FDA has approved the PD-1 inhibitor nivolumab for patients with unresectable or metastatic melanoma following treatment with ipilimumab or a BRAF inhibitor.

The Evolving Treatment Landscape in Advanced Melanoma

December 18th 2014

Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.

Dr. Davids On Ipilimumab for Hematologic Malignancy Treatment

December 17th 2014

Preparing for the Future

December 15th 2014

In attending the Society of Urologic Oncology's annual meeting in Bethesda in early December, I was struck by the number of presentations focusing sharply on the burgeoning fields of biomolecular markers and immunotherapy and their application to urologic oncology.